Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study

Claudia Bianco; Barbara Rossetti; Roberta Gagliardini; S Lamonica; L Fanti; Francesca Lombardi; Roberto Cauda; Simona Di Giambenedetto; Andrea De Luca

doi:10.7448/IAS.17.4.19816

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study

Claudia Bianco, Barbara Rossetti, Roberta Gagliardini, S Lamonica, L Fanti, Francesca Lombardi, Roberto Cauda, Simona Di Giambenedetto, Andrea De Luca

Research output: Contribution to journal › Conference article › peer-review

Abstract

Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART.

Original language	English
Pages (from-to)	19816-19816
Number of pages	1
Journal	Journal of the International AIDS Society
Volume	17
DOIs	https://doi.org/10.7448/IAS.17.4.19816
Publication status	Published - 2014
Event	HIV Drug Therapy Glasgow - Glasgow Duration: 2 Nov 2014 → 6 Nov 2014

Keywords

HIV
bone

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7448/IAS.17.4.19816

Cite this

Bianco, C., Rossetti, B., Gagliardini, R., Lamonica, S., Fanti, L., Lombardi, F., Cauda, R., Di Giambenedetto, S., & De Luca, A. (2014). Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. Journal of the International AIDS Society, 17, 19816-19816. https://doi.org/10.7448/IAS.17.4.19816

@article{c5ad6ca81ac548d8ab3b51cab54b5d94,

title = "Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study",

abstract = "Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART.",

keywords = "HIV, bone, HIV, bone",

author = "Claudia Bianco and Barbara Rossetti and Roberta Gagliardini and S Lamonica and L Fanti and Francesca Lombardi and Roberto Cauda and {Di Giambenedetto}, Simona and {De Luca}, Andrea",

year = "2014",

doi = "10.7448/IAS.17.4.19816",

language = "English",

volume = "17",

pages = "19816--19816",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "John Wiley & Sons Inc.",

note = "HIV Drug Therapy Glasgow ; Conference date: 02-11-2014 Through 06-11-2014",

}

Bianco, C, Rossetti, B, Gagliardini, R, Lamonica, S, Fanti, L, Lombardi, F, Cauda, R, Di Giambenedetto, S & De Luca, A 2014, 'Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study', Journal of the International AIDS Society, vol. 17, pp. 19816-19816. https://doi.org/10.7448/IAS.17.4.19816

TY - JOUR

T1 - Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study

AU - Bianco, Claudia

AU - Rossetti, Barbara

AU - Gagliardini, Roberta

AU - Lamonica, S

AU - Fanti, L

AU - Lombardi, Francesca

AU - Cauda, Roberto

AU - Di Giambenedetto, Simona

AU - De Luca, Andrea

PY - 2014

Y1 - 2014

N2 - Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART.

AB - Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART.

KW - HIV

KW - bone

KW - HIV

KW - bone

UR - http://hdl.handle.net/10807/61163

U2 - 10.7448/IAS.17.4.19816

DO - 10.7448/IAS.17.4.19816

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19816

EP - 19816

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow

Y2 - 2 November 2014 through 6 November 2014

ER -

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this